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ABSTRACT
Association of the Major Histocompatibility Complex
with Autism
by
Wayne W. Daniels, Master of Science
Utah State University, 1996
Major Professor: Dr. Reed P. Warren
Department: Biology
The pathogenesis of autism has proven difficult to
characterize.

However, in many recent studies, it is

suggested that the onset of this disorder is the result of
multiple etiological factors, which include genetic,
immunologic, and viral elements.
Possible immunological influences found in
subpopulations of patients with autism include decreased
lymphocyte responsiveness, reduced natural killer cell
activity, abnormal .response to rubella vaccine, abnormal
immune response to brain tissue, and decreased plasma levels
of the fourth component of complement(C4).

These aberrations

and others imply a possible autoimmune mechanism in some
cases for the development of autism.
C4 deficiencies have been found in subjects with
established autoimmune disorders, such as systemic lupus
erythematosus and chronic active hepatitis, in recent
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investigations. There is also evidence that the major
histocompatibility genes play an intimate role in autoimmune
processes.

Therefore, in knowing that the C4 genes are

closely linked to the major histocompatibility genes, this
study determined and analyzed the human leukocyte antigen
profile of autistic patients, their siblings, and parents.
In this study, it was found that the C4B complement null
allele occurred in autistic patients at nearly twice the
frequency compared to normals.

However, the C4A complement

null allele frequency was not found to be significantly
altered.

Several extended haplotypes were represented within

the patients studied.

However, the extended haplotype B44-

SC30-DR4 was the only one found at a significantly increased
frequency.

Further investigations are needed to better

understand the significance of these findings.
(64 pages)
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CHAPTER

I

INTRODUCTION
Autism is a developmental disorder characterized by
impaired social development and limited communication skills.
A definitive etiological agent for this disorder has not yet
been established; however, the pathogenesis of autism is
likely a result of multiple factors based upon genetic,
immunologic, and viral mechanisms.

Some recent

investigations suggest that autism demonstrates several
features characteristic of established autoimmune disorders,
such as genetic predipostion,l presence of antibodies against
brain antigens,2,J,4 sex differencess (autism is four to five
times more common in boys than in girls), and other immune
abnormalities.
Many genes whose products are involved in various immune
responses are found within the major histocompatibility
complex (MHC) located on the short arm of the sixth human
chromosome.

The combination of genes found within the MHC is

referred to as an MHC haplotype.

Interestingly, it has been

found that within the MHC, crossing over occurs at a reduced
frequency, resulting in
many generations.

haplotypes remaining unchanged for

A haplotype exhibiting this behavior has

been termed an extended haplotype.6
In Caucasians, extended haplotypes make up approximately

25-30% of all MHC haplotypes and are of importance because
they are associated with various clinical manifestations.
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For example, the extended haplotype HLAB*8, BF*S, C2*C,
C4A*QO, C4B*l, HLADR*3, abbreviated B8-SC01-DR3, is strongly
associated with systemic lupus erythematosus (SLE)

.1

The

actual pathogenic relationship between B8-SC01-DR3 and SLE
remains obscure but a plausible explanation for this
association may be the presence of a null allele at the C4A
gene of this extended haplotype.

A null allele is

functionally silent (yields no functional gene product) and
therefore results in reduced plasma levels of C4 protein.
This C4 deficiency may hinder various complement functions
including the capacity to prevent the precipitation, or
proper clearing, of immune complexes.
Immune abnormalities have also been reported to be
associated with the C4B locus.

For instance, high anti-

cytomegalovirus antibody titers (IgG isotype) have been
observed in patients with reduced C4B plasma levels.a
Moreover, persons carrying two null alleles at the C4B loci
have an increased number of infections of bacterial
meningitis9 and with Streptococcus pneumoniae, Haemophilus

influenzae, and Neisseria meningitidis infections.1o
Low levels of complement C4 protein have been found in
autistic subjects.ll

In addition, an increased frequency of

the extended haplotype B44-SC30-DR4, which contains a C4B
null allele, has been reported in the same autistic group.12
In other studies, possible viral associations have been found
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between autism and rubella or cytomegalovirus infections.13,14
Many autistic children frequently lacked rubella antibodies
in spite of previous vaccinations.1s

These investigations

suggest something is awry in the immune system of autistic
children.

Therefore, an investigation of immune mechanisms

and their possible relationship to autism seems worthwhile.

4

CHAPTER
LITERATURE

II

REVIEW

AUTISM
Autism is a developmental disorder that occurs at a
frequency of two to five cases per 10,000 individuals with
the rates of the disorder four to five times higher in males
than females.16

An estimated 75% of autistic individuals

function within a retarded range.17

The incidence of births

of children with autism appears to be seasonal, _peaking
mostly in March .1e, 19, 2o, 21

The existence of seasonal

flucuations suggests the involvment of an infectious agent,
such as a virus, which often causes epidemics during winter
months, as a potential etiological factor in some cases of
autism.

Persons diagnosed with autism appear to have normal

life spans and normal physical appearance.

Early diagnosis

.of autism is -important : because the child may begin treatment
before his or her condition has deviated too far from normal.
However, diagnosis of autism before the age_ of 12 months is
difficult because no signs indicate the presence of autism
during infancy.

By definition, the onset of autism must

occur before the child completes his or her third birthday.l6
There are three types of behavioral symptoms observed in
autistic children.

These symptoms form the principal
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criteria used in the diagnosis of autism22 and are classified
as the following categories:

1. Abnormal

development

of

social

relationships.

There is wide variation in the degree of expression of each
behavioral symptom depending on the severity of the disorder
and the age of the patient .

Consequently, a symptom

exhibited in one child may differ markedly in another.

An

autistic child encounters difficulty entering into and
maintaining normal relationships with other people.

He or

she may treat people as inanimate objects, often unaware or
unresponsive to feelings or emotions of others.

For example,

an autistic child's mother may be injured and in great pain.
The child will observe the mother's reaction without any
emotional response at all, as if he is bewildered and
confused by the mother's conduct.

2. Impairment of eommunication.

Many children with

autism do not develop a useful form of speech (i.e. they do
not produce sounds of recognizable words) .

Many of those who

do achieve well developed speech have other speech
abnormalities.

These abnormalities may include echolalia in

which the child repeats a word or phrase spoken by another
person or uses neologisms, words that have a specific meaning
not understood or used by others.

Also, children with autism

do not appear to use, to be aware of, or to interpret non-
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verbal forms of communication .such as facial expressions,
gestures, eye-to-eye contact, etc.
3.

Child's

interests

and repetitive.

and

activities

are

restricted

Autistic children show to some degree an

obsession with the maintenance of sameness.

Variations of

routine activities or environment may greatly disturb the
child, who usually responds to the change with some sort of
tantrum.

For instance, one child has violent tantrums if his

mother puts on a new dress, making it necessary for her to
purchase many dresses of the same color and pattern so as to
"keep the peace."

Another autistic child makes straight long

lines of bricks for hours, lining the bricks up in exactly
the same way and in the same precise sequence of colors.

GENETIC

FACTORS

IN

AUTISM

Bolton and Rutter have suggested that most cases of
autism include some underlying genetic factor.23

This

estimate is supported by two twin studies carried out in
different countries, England and Norway.

The English study24

found a 36% concordance rate for autism in monozygotic twins
versus a 0% concordance rate in dizygotic twins.

The second

study2s reported an amazing 89% and 0% concordance rate for
autism in monozygotic and dizygotic twins, respectively.
These results strongly suggest that a significant genetic
influence exists.
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Ritvo et al.26 studied 46 families with multiple
incidences of autism and found evidence for an autosomal
recessive form of inheritance.

The same workers later

completed an epidemiological study27 that revealed a 215 times
greater chance of a person having autism if he or she is a
sibling of a child with autism. It is thus evident that the
etiology of many cases of autism is genetically based.

AUTISM AS
DISORDER

AN

AUTOIMMUNE

Efforts in understanding the etiology of autoimmune
diseases have proven to be formidable.
lack of

However, despite a

thorough understanding of this phenomenon, a genetic

influence is suspected in autoimmunity.

This suspicion is

_based on findings of multiple incidence of an autoimmune
disease within a family.

Interestingly, Money et a1.2a

reported a case of a child with autism and an autoimmune
disease, Addison's disease (this child also had moniliasis).
Moreover, two older brothers exhibited various clinical
conditions including hypoparathyroidism, Addison's disease,
moniliasis, and alopecia totalis.

A third brother and

parents were healthy and asymptomatic of any identifiable
disease condition.

The authors concluded that the autistic

state might have been attributed to autoantibodies in some
way affecting the central nervous system.2a
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Other autoimmune disorders including systemic lupus
erythematosus29 and rheumatoid arthritisJo have been found in
families of autistic children.

Autoantibodies to brain

serotonin receptors in autistic subjects have also been
reported.31

In other studies, evidence has been found for

immune reactivity to neural-tissue.

These include studies

performed by Weizman et al.2 and Singh et al.,32 in which
there was a lymphocyte response and formation of
autoantibodies, respectively, to human myelin basic protein.
Moreover, Plioplys et al.33 found the presence of
autoantibodies to a different brain antigen, the 210K
neurofilament.

These same authors showed an abnormally

increased percentage of OR-positive T-cells lacking IL-2
receptors in 17 autistic patients.4

This finding of DR-

positive T-cells lacking IL-2 receptors in autistic patients
was confirmed by Warren et al.34 and is a characteristic seen
in autoimmune diseases.

COMPLEMENT
The complement activation system is one of many immune
defense mechanisms that provides protection against pathogens
via two pathways: the classical pathway and alterative
pathway.

Both pathways function in the extracellular fluid.

The classical pathway consists of nine proteins that
participate in a sequential cascade of reactions.

Cl, the
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first protein of the pathway, is activated by an antibody
bound to a membrane surface.

The actual sequence for the

classical complement components is Cl-C4-C2-C3-C5-C6-C7-C8-C9
(see Figure 1) .

The first five components have enzymatic

activity and are considered to be proenzymes (precursors of
inactive form of enzyme).
attack complex (MAC) .

· The last four form a membrane

This complex of proteins, the MAC,

aggregates to form a hollow cylinder that is inserted into
the membrane of the pathogen.

This cylindrical complex

functions by allowing cellular material to "leak" out and,
more importantly, water to enter.

The osmotic pressure

causes cell lysis, destroying the pathogen.
The alternative pathway differs from the classical
pathway in one fundamental way: how the pathway is initiated.
The alternative pathway is triggered by C3 spontaneously
attaching to a membrane surface, to microbial agents, to IgA,
or to IgG4.

Again, a sequence of reactions takes place with

additional complement components Factor B, Properdin, and
Factor D.

The remaining components of this pathway, CS

through C9, are the same as for the classical pathway with
the same result of cell lysis.

Thus, the latter stages of

each pathway are shared between both the classical and
alternative pathways.

The alternative pathway is part of the

innate immune system that is nonspecific and active at all
times.
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Classical

Alternative

Pathway

Pathway

Cl

B

C3

cs
C6
C7
C8
C9
Forma.tion of membrane channels

Fig. 1. Complement system pathways.

DIFFERENCE
AND C4B

BETWEEN

C4A

C4A and C4B, the two major isotypes of C4, are encoded
by two closely linked genes within the MHC.

The two genes

are nearly 98% homologous, and extensive polymorphism is
observed at their respective loci.

Each C4 locus produces
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one large peptide chain that undergoes posttranslation
modifications, such as internal cleavage and the formation of
disulfide bonds to yield tripeptide molecules.

The three

subunits of the molecule have been labeled alpha, beta, and
gamma, the alpha being the largest and the gamma chain being
the smallest.
When a C4 molecule is activated (cleaved by C1s), a
small fragment of the amino end of the a chain is cleaved
off .

Removal of this small fragment exposes two activation

sites.

One is involved in the binding complement protein C2,

and the other is an unstable internal thioester bond.

The

latter is responsible for attaching the C4 molecule to a
membrane (or antigen) surface and for the unique functional
differences observed between C4A and C4B molecules.

C4A

appears to preferentially bind to amino-rich surfaces by
forming amide linkages via hydrolysis of the thioester bond;
C4B tends to form -ester linkages from hydrolysis of the same
bond.35

This difference in avidity to distinct functional

groups is believed to be responsible for the unique functions
of C4A and C4B.

For example, C4B is four times more

hemolytic to sheep red-blood cells than C4A.

This is likely

due to a predominance of hydroxyl groups on the red bloodcell surface and therefore the greater deposition of C4B on
the membrane.

Other functional differences between C4A and

C4B may be similarly explained.
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FUNCTIONAL ROLE
COMPLEMENT

OF

Although complement provides a defense mechanism by
causing cell lysis, additional protection is accomplished
through a process termed opsonization.

Opsonization is a

process in which foreign particles are "marked" for cellular
uptake by fragments of complement components produced by
enzymatic cleavage during activation of the complement
pathways.

The C3b and C4b complement fragments are referred

to as opsonins, and when deposited on a cell surface act as
ligands for phagocytic cells.
enhanced phagocytic efficiency.

This mechanism provides
Therefore, the clearance and

elimination of potential pathogenic organisms are increased
via opsonization.

C4B NULL
AUTISM

ALLELE

AND

One of the primary objectives of this project is to
provide data to suggest a possible association of a C4B null
allele with autism. A null allele is a an allotype that does
not produce a functional gene product.

The null allele may

not produce any gene product at all or may produce an
inactive gene product.

In earlier studies it is suggested

that autistic patients have a higher incidence of a null
allele at the C4B locus than patients without the disorder.l2
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The presence of a C4B null allele constitutes a complementcomponent deficiency and results in decreased serum levels of
C4B protein.

Low levels of any complement component may

limit the defensive mechanism provided by the complement
activation system.

EXTENDED

MBC

HAPLOTYPES

The major histocompatibility complex (MHC) is located on
the short arm of human chromosome 6.

Within this region of

about three million base pairs lie many genes involved in the
immune system (see Figure 2) .

The combination of all alleles

within the MHC determines the haplotype for the chromosome
observed.

Therefore, a person will normally have two

haplotypes (one for each chromosome 6) .

These genes have

been categorized into three classes: I, II, III.

From the

centromere the MHC gene classes are arranged in the following
order: MHC II-MHC III-MHC I .

.Most MHC I and MHC II gene

products are cell surface proteins.

However, MHC III

proteins are not directly associated with a cell membrane.
MHC I gene functions involve processing and presentation of
antigens (small peptides) to T-cells, primarily CD8+ T-cells.
While MHC II genes also function in antigen processing and
presentation, their interaction is primarily restricted to
CD4+ T-cells.

MHC III genes code for a variety of products

and have a wide array of functions, including cytokine
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signaling and complement function.

The three class III genes

studied in this project are C4A, C4B, and Bf.
DR
Centromere

Fig. 2.

C4B

C4B

C2

B

BF

--1---//---1-----1----1----1---//---1-- Telomere

Simple schematic of the MHC on chromosome 6.

An extended MHC haplotype is a fixed conserved region
within the MHC usually defined by HLA-B (MHC II), complotype
Bf,C2,C4A,C4B, and HLA-DR (MHC II) alleles.6

However, the

conserved region may extend beyond these genes.

Because

these genes behave as if they are "fixed," they are inherited
as a group, showing a lower frequency of crossing-over than
expected.

This phenomenon is referred to as linkage

disequilibrium.6

NBC-DISEASE

ASSOCIATION

Linkage disequilibrium is one of two distinguishing
features of the MHC.
polymorphism.

The other is extensive genetic

Extensive polymorphism is a possible selective

advantage for survival and, conversely, there is a
possibility of association of certain diseases with
particular MHC profiles (HLA profile), or haplotypes.
such associations have been identified.

Many

For example, it has

been found that a person whose HLA profile includes HLA-B27
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has an 87.4 times greater risk of developing Ankylosing
spondylitis than a person without HLA-B27.36
association.

This is a strong

The most common extended haplotype studied to

date is designated B8-SC01-DR3 and has been found to be
associated with several disease conditions including
generalized mysthenia gravis, IgA deficiency, and systemic
lupus erythematosus.37
The mechanism responsible for the association of a
particular MHC profile and disease remains unclear.

However,

the MHC's central role in processing and presenting foreign
antigens for elicitation of an immune response is a possible
explanation.

One possibility is that the MHC proteins are

not able to adequately process a pathogen and thereby
activate necessary mechanisms for a host to mount an immune
response.

This inability of the host to defend itself

immunologically would allow the pathogen to cause sufficient
damage to result in disease.

MBC CLASS
REGIONS

II

BYPERVARIABLE

Of all human genes known, MHC genes are thought to
exhibit the highest degree of allelic polymorphism.

The MHC

Class II complex consists of two peptide subunits termed
alpha and beta.

Together, the two subunits fold to form an

"antigen binding groove" where fragments of foreign proteins,

6 to 25 amino acids long, are loaded following degradation
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processes.38,39

These degraded fragments then act as antigens

when presented in conjunction with MHC molecules to T-cell
receptors.

Most T-cells can only respond to antigens

presented in this fashion.

This is the commonly known

phenomenon of MHC restriction.
Interestingly, in allelic variants of HLA-DR molecules,
nearly all the polymorphisms are contributed by the beta
subunit,40 most of which lie in three areas termed the
hypervariable regions (HVRs) .

Correlation of polymorphic

sites to the tertiary structure of the HLA-DR molecule is
evident of an assignment of the hypervariable regions to the
antigen-binding groove of the MHC complex.41

This implies

that the antigenic fragment lying within the antigen-binding
groove is in direct, or at least close, contact with the HVRs
of the MHC subunits.

The HVRs provide a crucial portion of a

framework for the selective interaction of MHC molecules with
antigenic peptides. 42

One ': antigenic . peptide may · bind to the

antigen-binding groove with greater affinity than another
peptide.43

Such selectivity determined by the HVR

specificities of the HLA molecules is the essence of the
strength and efficiency of an immune response.44
HLA-DR allotypes can be further subtyped through
analysis of amino acid sequences coded by the DRBl gene.
More specifically, the heterogenicity of the HLA-DR4 subtypes
can be traced to and identified by amino acid differences at
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positions 37, 57, 67, 70, 71, 74, and 86 of the beta
subunit.45

Based on sequence specificities, the subtypes are

designated DRB1*0401, DRB1*0402, DRB1*0403, etc.

The

variations between subtypes may exist at one, two, or all
three HVRs.
Several research groups are studying potential roles HVR
specificities may play in disease pathogenesis.

Matsushita

et al. noted that patients with methimazole-induced insulin
autoimmune syndrome express the DRB1*0406 allele and not
DRB1*0405 allele.46

The group performed binding assays in

which a small peptide fragment of human insulin alpha chain
bound with much greater affinity to DRB1*0406 than to
DRB1*0405.

The authors conclude that presentation of the

small fragment by antigen-presenting cells may lead to
activation of self-insulin-specific T-helper cells.

Another

study47 performed by Topham et al. looked at experimental
autoimmune encephalomyelitis (EAE), which represents a mouse
model for human multiple sclerosis.

Mice were vaccinated

with an 18-amino acid peptide from HVR3 of the mouse MHC
class II beta chain.

The treatment elicited auto-antibodies

to the small beta peptide and aided in preventing and
treating EAE.

A similar avenue may be useful in the

treatment of human autoimmune diseases associated with
specific HVR sequences.
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CHAPTER
MATERIALS

III

AND

METHODS

SUBJECTS
One hundred twenty-four subjects were included in this
study; 45 autistic child subjects, 30 normal child subjects,
and where possible, the parents of each participating child
were also analyzed by the same methods.

Diagnosis of

infantile autism was made by using DSM-IIIR criteria as
established by at least two psychiatrists or psychologists.16
All subjects were of Northern European descent and were
living in the same geographical area (Northern Utah) at the
time of this study.

In addition, all normal subjects were

screened for possible autoimmune disorders (e.g., adolescent
diabetes) .

PLASMA

PREPARATION

Blood samples used in this study were collected via
venipuncture following informed consent procedures.

Freshly

drawn samples were centrifuged at 2,000 rpm (900x g) for 10
minutes.

Plasma was stored at

ELECTROPHORESIS
AND

OF

-7o·c

until used.

C4A

C4B

Prior to electrophoresis, plasma samples were treated
with two enzymes, Neuraminidase Type V and Carboxypeptidase B
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Type II (both from Sigma, St. Louis, MO).

Approximately 0.13

units of neuraminidase were added to 10

of plasma and

incubated for 18 hours at
incubation at 37"C.

4·c

~1

followed by 1 hour of

Approximately 1 to 1.3 units of

carboxypeptidase B were added to each sample and incubated
for 30 minutes at room temperature (=25.C).
Agarose gels (SeaKem ME Agarose, FMC) were prepared with
electrophoresis buffer (8 mM Barbital, 32 mM Sodium Barbital,
37 mM Gylcine, and 19 mM Tris[hydroxymethyl]aminomethane)and
distilled H2 0. Approximately 13 ml of liquified 0 . 7% agarose
was loaded on the hydrophilic side of a 10-cm x 10-cm
electrophoresis film (i.e. gel bond) to create a 1.3-mm thick
gel.

Sample wells were formed in the gel with the use of a

15-well, 0.75-mm comb (BioRad, Hercules, CA).

The gel was

allowed to cool and solidify.
The gel was placed on a cooling plate (Horizontal
Electrophoresis Cell, BioRad, Hercules, CA) at
wells near the cathode.

4·c

with the

Wicks were placed at both ends of

the gel so as to bridge the buffer chambers and the gel.
Four microliters of treated samples were loaded into each
well.

The same volume of sickle cell hemoglobin (HbS, Sigma,

St. Louis, MO) was loaded in the two outermost wells.
Electrophoresis was terminated when the HbS markers migrated
7 em anodally (about 3 hours) .

Electrophoresis was performed
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at 400 constant volts while limiting the. current at 200 rnA
and the power at 200 W.

IMMUNOFIXATION AND
STAINING OF C4
Following electrophoresis, the gel was removed from the
refrigerated plate, and 0.5 ml of a 3:2 dilution of antihuman C4 antibody and distilled water (Atlantic Antibodies,
Stillwater, MN) was spread on the surface of the gel {about
5~1/cm2).

The gel was placed in a humidified box for 2 hours

at room temperature.

The antibody diffused into the gel and

bound to C4 present to form a large antigen-antibody complex.
This process is referred to as immunofixation because the
antigen-antibody complex becomes insoluble and is immobilized
within the gel.
When immunofixation was complete, filter paper (Whatman
No.5) was placed over the gel with light pressure to absorb
excess or unbound antibody.

The gel was then placed in 1X

phosphate buffered saline solution (PBS, 1.9 mM sodium
phosphate monobasic, 8.1 mM sodium phosphate dibasic, 154 mM
sodium chloride, pH 7.4) overnight so any protein not bound
by the anti-human C4 antibody could diffuse out of the gel.
Therefore, only the complexed C4 protein remained in the gel.
The next day the PBS was replaced with fresh PBS twice, one
hour for each change.
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Next, the gel was dried with a hair dryer.

The dried

gel was placed in a staining solution (1% Coomassie Brilliant
Blue G-250, J.T. Baker) for 10 minutes, then in a destaining
solution until the background was clear compared to the
stained bands.

The gel was preserved by rinsing in a 10%

glycerol solution and dried again using a hair dryer.

At

this point blue "spots," or bands, may be visualized within
the gel.

These bands represented various C4 alleles and were

used for designating specific C4 allotypes for each patient.

C4

ALLOTYPING
C4 allotyping, or complotyping, is based on the relative

migration rates of C4A and C4B.
common C4 allotypes in humans.48

C4A3 and C4B1 are the most
The distance between these

two bands is taken as a standard of unity.

Where a band is

located relative to the band positions of C4A3 and C4B1
determines its designated allotype.

The appearance of a

single faded or weak band strongly suggests the presence of a
C4 null allele.

The presence of a null allele can be

supported by a corresponding faded band in the plasma of one
of the patient's parents.

Also, the patient's measured C4

protein serum level is expected to be low or moderately low.
A patient with one C4B null is considered heterozygous for
the C4B gene.

If no C4B bands are visualized, the patient
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likely has two C4B null alleles and is considered homozygous
for the gene.

PREPARATION
EXTRACTION

OF

CELLS

FOR

DNA

Ten milliliters of venous whole blood were layered over
4 ml Histopaque 1077 (Sigma, St. Louis MO) and centrifuged
for 20 minutes at 1,000x g.

Human peripheral blood

mononuclear cells (PBMC), located at the top of the
Histopaque solution (i.e. at the interface), were transferred
to a 15-ml conical bottomed tube, and the volume was brought
to 10 ml with RPMI-1640 (Gibco Lab, Grand Island, NY) .
tube was centrifuged at 500x g for 10 minutes.

The

The pellet

was then resuspended in 5 ml RPMI-1640 and centrifuged a
second time at 200x g for 5 minutes.

Finally, the pellet was

resuspended in 5 ml RPMI-1640 and 3 x 106 PBMCs were
transferred into a 25-cm2 tissue culture flask containing 10
ml HyQ Cyte L (HyClone Lab, Logan UT) and 1%
phytohemaglutinin (PHA)

(Gibco Lab, Grand Island, NY) .

The

flask was incubated for 5 days at 37·c.

EXTRACTION
B TYPING

OF

DNA

FOR

FACTOR

After a patient's PBM's had proliferated to a
concentration of 106 to 107 cells/ml (see above), the cultured
solution was centrifuged at 2,000 rpm (900x g) for 10
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minutes.

The supernatant was removed and 240

~1

of lysis

buffer (0.28 M sucrose, 10 mM Tris-HCL at pH 7.5, 5 mM MgC1 2
and 1% Triton X-100) and 18

~1

of Pronase E (20 mg/ml, Sigma,

St. Louis, MO) were added to the pellet and mixed well.

This

mixed solution was transferred to a microtube.
Twelve microliters of .20% sodium dodecyl sulfate were
added and the mixture was incubated at
hours (overnight) while shaking gently.

ss·c

for 12 to 16

An equal volume of

phenol was added to the incubated mixture and vortexed for 15
minutes followed by centrifugation, 14,000 rpm, for 10
minutes.
microtube.

The aqueous layer was transferred to a separate
Again, an equal volume of phenol was added

followed by vortexing, centrifugation, and transfer of
aqueous phase as mentioned above.

An equal volume of 25:1

chloroform:isoamyl alcohol was added to the transferred
aqueous solution and vortexed for 15 minutes followed by
centrifugation in a microcentrifuge at 14,000 . rpm (6,000x g)
for 10 minutes.

The aqueous phase (top layer) was

transferred to a separate microtube.
The DNA was precipitated by adding 0.1X volume of 3 M
sodium acetate and 1.5X volume of isopropanol.

The

precipitated DNA was spooled onto the tip of a pasteur pipet
and placed in 0.5 ml TE buffer (10 rnM Tris, 1 nM EDTA) to
dissolve the DNA.

A O.SX volume of 7.5 M ammonium acetate

and 2X volumes ice-cold ethanol (100%) were added to the DNA
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to reprecipitate it.
fresh microtube.
200

~1

sample.

The DNA was spooled. and placed into a

The ethanol was allowed to evaporate, and

TE-4 buffer (10 nM Tris, 0.1 mM EDTA) was added to the
The DNA was dissolved overnight. DNA concentration

was determined spectrophotometically at O.D. 260 nm and a
measure of DNA purity was determined by obtaining a 260/280
ratio.

METHODS

FOR

TYPING

FACTOR

B

The two methods used for allotyping of the Factor B gene
(Bf gene) were polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP) .
50-~1

For PCR, a

solution was prepared with the following reactants:

patient's DNA (1

~g/ml),

1.5 rnM MgC1 2 ,

200

~

deoxynucleotide

phosphate bases, 1X PCR buffer (Promega Corp., Madison, WI),
1

~M

of each primer (5'AAGTGATGTGGGTAGGACAGGC3' and

5'TGCAGTCTGCCTTCCTGACAGTCT3'), and 2 units of Taq DNA
Polymerase (Promega Corp., . Madison, WI).

Finally, an equal

volume of mineral oil was placed on top of the prepared
solution to prevent evaporation.

PCR was carried out for 30

cycles in an Ericomp thermal cycler.

Each cycle consisted of

a 1-minute denaturation at 94"C, a 2-minute annealing at
64"C, and 2-minute extension at 72"C.

A 593-bp

oligonucleotide PCR product was detected by agarose gel
electrophoresis.

Four microliters of the PCR product and 2
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~1

of tracking dye (50% glycerol,

bromophenol blue, 10

0~25%

mM EDTA) were combined and loaded onto a 2% NuSieve Agarose
(FMC Bioproducts, Rockland, ME) gel in a 1X Tris acetate
buffer (0.04 M Tris-acetate, 0.001 M EDTA, 0.5
bromide) .

~g/ml

ethidium

A DNA size marker (1 Kb DNA ladder, Gibco BRL,

Gaithersburg, MD) was loaded in the gel to estimate the
approximate the size of the PCR product and ensure proper
amplification of desired DNA region.
rnA for approximately 40 minutes.

The gel was run at 100

The gel was placed on a UV

light transilluminator and the DNA was detected by
fluorescence of ethidium bromide.

Photographs of each gel

were taken for ease of storing collected data.
Samples with positive PCR amplification were analyzed
for the Mspi RFLP of the BF gene.

The PCR product was

digested with the isoshizomers Mspi or Hpaii (Promega Corp.,
Madison, WI) in the · following manner.
solution was prepared by combining 6
~1

product, 3
and 20.7

~1

A
~1

30-~1

reaction

of the amplified

lOX buffer for enzyme, 3 units :of endonuclease,

sterilized dH 2 0.

The solution was vortexed

gently and placed in a 37•c waterbath overnight.

Next, 10

~1

of tracking dye were added to each sample and loaded in a 4%
NuSieve Agarose gel.
per well.

The gel was loaded with 40

~1

of sample

Again, a DNA size marker (lKb DNA ladder, Gibco

BRL) . was also loaded along with samples.

The buffer used was
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a lX Tris-acetate-EDTA buffer with ethidium bromide.
Electrophoresis ran for 50 minutes limited at 100 rnA.
The DNA fragments were visualized on a transilluminator
and photographs taken.

The S allotype of the Bf gene

contains an Mspi site that produces two fragments after
digestion of approximately 400 and 200 bp.

An uncut 600 bp

fragment depicted an F allotype of the Bf gene.
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RESULTS

C4

ANALYSIS

In Figure 3, an immunoelectrophoresis gel of treated
plasma samples is depicted.

The dark uppermost and lowermost

bands are the reference C4A and C4B allotypes, respectively,
which serve as reference points for C4 allotyping.

The

uppermost band is C4A3 and the lowermost band is C4B1.

The

distance between C4A3 and C4B1 is given a reference value of
100.

Where other C4 allotypes migrate with respect to C4A3

and C4B1 determines its designated phenotype. Figure 4 is a
RFLP electrophoresis gel for Factor B.
marker.

Lane 1 is a DNA size

In lane 2 there is an endonuclease cut site on one

chromosome, represented the 200bp and 400bp bands (S
allotype), and the lack of the same endonuclease cut site on
the other chromosome, represented by the 600bp band 9F
allotype) .

In lane 3 there is only the 600bp band (therefore

homozygous F), while in lane 4 there are the 400bp and 200bp
bands, but not the 600bp band (therfore homozygous S) .
At least one C4B null allele was found in 22 of 45 (49%)
autistic subjects (Figure 5) .

However, only 16 (20%) of the

79 normal subjects carried the same allele.

This increase in

the number of C4B null alleles found in the autistic subjects
was statistically significant (p <0.001).

Of the 21 autistic
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Lane
Fig. 3.

3

4

5

Gel analysis of C4A and C4B phenotypes.

Lane
Fig. 4.

2

1

1

2

3

4

RFLP analysis of Factor B.
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Fig. 5.
Percentage of autistic subjects, their parents, and
unrelated healthy controls expressing a C4B null allele.
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patients who did carry a C4B null allele, 8 carried an
additional C4 null allele, C4A or C4B, on the homologous
chromosome.

A C4A null allele was carried on 20 of 45

(44%)

of the autistic subjects and on 37 of 79 (47%) of the normal
subjects.

This was not found to be significant

statistically.

Although the importance is not known, two C4

null alleles were never found to be carried on the same
chromosome.
The percentages of C4B and C4A null alleles of the
-

parents of the autistic patients and controls are included in
Figures 5 and 6, respectively.

The purpose of including the

parental data was to see if perhaps C4 null alleles were
inherited more maternally or paternally.

As can be observed

from Figures 5 and 6, no such tendency is evident.

However,

if a child expressed a null allele, at least one parent also
carried a null allele.
The C4 allotypes of patients, autistic and nonautistic,
carrying a C4B null allele are given in Table 1.

No one

allele was found to be significantly associated with a C4B
null allele in the presence of autism.

EXTENDED

HAPLOTYPE

ANALYSIS

Ten different extended haplotypes (Table 2) were
observed in this study of autistic and normal subjects
randomly selected from the general Northern Utah population.
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Fig. 6.
Percentage of autistic subjects, their parents, and
unrelated healthy controls expressing a C4A null allele.
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Table 1.

C4 allotypes in patients with C4B null alleles
Autistics (n - 21)

0

1

C4Aa
C4Ab 7
C4Bb 1

2

3

3

21
11

18

1

4

5

Nonautistics (n -

6

2

1

1

0

1

1

2

2

. 3

4

1

4

1

4

1

5

4

This is the C4A allotype found on the same chromosome as
the C4B null allele.
b These are the C4 allotypes found on the chromosome not
carrying the C4B null allele.
a

6)

6
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Table 2. List of extended haplotypes observed in this study
Class

Class

Class

I

II

III

DR

DRB1

Abbreviation

1

5

0501

B7-SC31-DR15

0

1

3

0301

B8-SC01-DR3

c

3

1

7

0701

B13:-SC31-DR7

F1

c

3

0

3

0301

B18-F1C30-DR3

35

F

c

3,2a

0

1

0101

B35-FC(3,2)-DR1

44

s

c

3

0

4

0401

B44-SC30-DR4

44

F

c

3

1

7

0701

B44-FC31-DR7

57

s

c

6

1

7

0701

B57-SC61-DR7

62

s

c

3

3

4

0401

B62-SC33-DR4

65

s

c

2

1+2

1

0101

B65-SC2(1,2)-DR1

B

Bf

C2

C4A

C4B

7

s

c

3

8

s

c

13

s

18

a This designation denotes . a rare duplication ·of the C4A gene
in which one allele is · expressed as C4A3 and the other allele
as C4A2. With the extended haplotype B35-FC(3,2)-DR1 it has
been shown that the gene duplication results from gene
conversion of B to A. The extended haplotype B44-SC30-DR4
has undergone a similar conversion but it is conventionally
designated as B44-SC30-DR4 instead of B44-SC(3,3)0-DR4.
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These 10 extended haplotypes were expressed on 53 of 90
(58.8%) (Table 3) chromosomes studied in the autistic
patients.

The same extended haplotypes were carried on only

33 of 128 (25.7%) chromosomes of unrelated normal subjects.
Also, mothers of the autistic children had an increased
representation of extended haplotypes, 41 of 78, compared to
that of the fathers, 31 of 78 (Table 3).

Many extended

haplotypes have been found to be associated with various
diseases.

Diseases known or suspected to be associated with

the extended haplotypes found in this study are displayed in
Table 4.
The phenotypic frequencies of the extended haplotypes
observed in this study are shown in Table 3.

Of the 10

extended haplotypes found in this study, only one B44-SC30DR4 was significantly increased (p <0.05).

B44-SC30-DR4 was

not represented in any of the 64 control subjects.
In addition to the

s~gnificant

representation of B44-

SC30-DR4, four autistic subjects had a fragment · of this
extended haplotype including SC30-DR4

(Table 5) (i.e. the

fragment SC30-DR4 includes the Class II and Class III regions
of this extended haplotype and a different Class I region
allele) .

Thus, the extended haplotype B44-SC30-DR4, or a

fragment thereof, is represented in nearly a third (29%) of
the autistic subjects as compared to less than 2% of the
unrelated healthy contr,ols,

Moreover, 12 mothers of autistic
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Table 3. Frequency of extended MHC haplotypes in autistic
subjects

Total

Ext. Haplotype

n = 45

Maternal

n

= 39

Paternal

n = 39

Healthy

n

= 64

B44-SC30-DR4

9(20.0)a

8 (20.5)a

3

BX-SC30-DR4b

4 (8.8)

4 (10.3)

2 ( 5. 1)

1 ( 1. 6)

B35-FC(3,2)0-DR1 2 ( 4 . 4)

0 (0)

3

1 ( 1. 6)

B18-F1C30-DR3

2 ( 4 . 4)

1 (2. 6)

1 (2. 6)

0 (0)

B62-SC33-DR4

2 ( 4. 4)

2 ( 5. 1)

2 ( 5 .1)

2 ( 3. 1)

B44-FC31-DR7

7 ( 15. 5)

4 (10.3)

4 (10.3) 4 (6.2)

B57-SC61-DR7

3 (6.7)

4 (10.3)

1 ( 2. 6)

2 ( 3. 1)

B13-SC31-DR7

3 (6.7)

2 (5. 1)

1 (2. 6)

1 ( 1. 6)

B65-SC2(1,2)-DR1 1 (2. 2)

1 (2. 6)

0 (0)

0 (0)

B7-SC31-DR15

7 ( 15. 5)

6 (15.4)

6 (15.4) 5 ( 7. 8)

B8-SC01-DR3

13(28.8)

9 (23.1)

8 (20.5) 17(26.6)

(7. 7)

(7.7)

0 (0)

a p <0.001 as compared to values from healthy controls.
b Fragment of the B44-SC30-DR4 extended haplotype including
SC30 and DR4 but with a HLA B marker other than 844.
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Tab1e 4. List of extended haplotypes observed

this study

and their reported disease associations49
Extended Haplotype

Disease Associations

B7-SC31-DR15

Multiple sclerosis, IgA deficiency

B8-SC01-DR3

Generalized myasthenia gra~is, IgA
deficiency, Systemic lupus erythematosus,
Celiac disease

B13-SC31-DR7
Bl8-F1C30-DR3

Insulin-dependent diabetes mellitus

B35-FC(3,2)-DR1

HIV rapid progression

B44-SC30-DR4

Rheumatoid Arthritis (child onset),
Feltys Syndrome

B44-FC31-DR7

Celiac disease, IgA deficiency

B57-SC61-DR7

IgA deficiency, Psoriasis

B62-SC33-DR4

Insulin-dependent . diabetes mellitus,
Rheumatoid Arthritis

B65-SC2(1,2)-SR1

IgA deficiency
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Tab~e

5.

B44-SC30-DR4 in autism

With
B44-SC30-DR4

With
X-SC30-DR4a

Subjects

N

Autistics

45

9 (20.0)b

4

(8.8)c

Mothers

39

9 (23.1)b

3

(7.7)

Fathers

39

3

2

(5.1)

Family normal chromosomesd

39

4 (10.3)

1

(2.6)

Unrelated controls

64

0 (0.0)

1

(1.6)

(7.7)

Fragment of B44-SC30-DR4 with identical DR, DQ and
complement alleles but with a different B region allele.
b p <0.001 as compared to unrelated controls.
c p <0.05 as compared to unrelated controls.
d Chromosomes of parents not segregating to autistic child.
a
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children carried B44-SC30-DR4 or its fragment. In all, · 18 of
45 (40%) of the autistic subjects or their mothers carried
B44-SC30-DR4 or its fragment.
Seven of the autistic subjects in this study had one or
more siblings also diagnosed with autism.

Their extended

haplotypes and those of their siblings are given in Table 6.
Interestingly, five of these subjects carried an extended
haplotype on both chromosomes, and a sixth subject carried an
extended haplotype on one chromosome.

Five autistic siblings

or sets of autistic siblings shared one or both extended
haplotypes expressed by the corresponding reference autistic
subjects.

One autistic subject (Subject 6 in Table 6)

carried an extended haplotype not received by the autistic
sibling, and one autistic subject (Subject 7) and sibling did
not express any extended haplotypes at all.
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Table 6. Sharing of extended haplotypes by autistic siblings

Subject

1. B8-SC01-DR3
B13-SC31-DR7
2. BX-SC30-DR4

B7-SC31-DR15
3. B44-SC30-DR4
B57-SC61-DR7
4 . B35-SC(3,2)0-DR1
B44-FC31-DR7
5. B62-SC33-DR4
B44-FC31-DR7
6. B44-FC31-DR7
None a

Sibling 1

Sibling 2

Sibling 3

B8-SC01-DR3

B8-SC01-DR3

B8-SC01-DR3a

B13-SC31-DR7

B13-SC31-DR7

None

BX-SC30-DR4

B8-SC01-DR3

B8-SC01-DR3

None

B7-SC31-DR15

B7-SC31-DR15

B44-SC30-DR4
None
B35-SC(3,2)0-DR7
None
B62-SC33-DR4
B8-SC01-DR3
None
Nonea

7 . None

None

None

None

a Subject 1 had an fourth sibling who also inherited B8-SC01DR3 and whose other chromosome did not express an extended
haplotype.
b Chromosome carries
B62-SC31-DR15-DRW52-DQ6, which is a
fragment of B7-SC31-DR15 (Table 1) .
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V

DISCUSSION
Two significant findings of this study include increased
frequencies of the C4B null allele and the extended haplotype
B44-SC30-DR4 among autistic patients.

The actual

relationship of either finding to autism is unknown, although
numerous mechanisms can be imagined.

One possibility is that

the extended haplotype B44-SC30-DR4 carries a functionally
silent C4B null allele.

The products of the C4 _ genes are

essential to the activation of other critical components of
complement pathways that provide protection against viruses,
bacteria, and other pathogens.

Increased frequency of C4B

null alleles has been reported in patients with scleroderma5o
and schizophrenia.51

In addition, accelerated disease

progression following seroconversion to HIV and certain
manifestations associated with AIDS have been associated with
C4 null alleles.

C4B null alleles have also been found to be

underrepresented in people 80 years of age or older. 52,53
This underrepresentation implies that expression of a C4B
null allele may have a deleterious effect on a person's longterm survival.

It is logical to conclude that a person

without the complement defense mechanism may have a greater
predisposition to disease by infectious agents.

41

A small subset of autistic patients in this study did
not carry a C4 null allele but their mothers did.

At first

glance this may argue against an association of a C4
deficiency with autism.

However, it is plausible, in some

cases, that the mother's immune defiency (i.e. having a C4
null allele) may be sufficient to allow a pathogen to persist
and cause damage to the fetus during gestation.
Interestingly, Laitinen et al. found spontaneous abortions to
be associated with C4 null alleles.S4
The relevance of B44-SC30-DR4 to autism may be through
the Class II markers expressed on this extended haplotype.
This study found the Class II and III portions (-SC30-DR4) of
B44-SC30-SR4 in 18 of 45 (40%) autistic subjects and/or
autistic mothers.

The Class II (DR and DQ) markers are

intimately involved in binding and presenting degraded
processed peptide antigens to T lymphocytes.

Class II

markers, with a peptide antigen ligand, interact with T-cell
receptor (TCR) molecules, resulting in activation of the
mature T lymphocyte.

If the Class II-TCR peptide complex

interaction occurs during maturation of the T cell in the
thymus, two types of selection will take place: positive and
negative selection.ss,s6

These selection processes allow T-

cells to differentiate into competent mature T lymphocytes.
During intrathymic development, negative selection appears to
eliminate T-cells specific for self peptides due to their
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potentially harmful effects. In the positive selection
process, T-cell receptors that interact with self MHC
molecules with appropriate affinity evade cell death.
other developing T-cells die.

All

Both processes are necessary

to acquire T-cell maturity, and both are intrinsic in
creating a T-cell repertoire that is unique to an MHC
haplotype of an individual.
Both the antigen selection and binding function of MHC
molecules are potential mechanisms that may explain HLA
disease associations.

The specific role of either mechanism

to any disease remains unknown.

However, several models have

been proposed to explain disease associations to MHC
haplotypes.s?

In the first model, it is suggested that the

MHC molecule itself operates as a receptor for the pathogen
or disease-causing agent.

Therefore, the MHC specificity

(i.e. an individual's haplotype) of an individual would
determine a pathogen's ability to infect a host and cause
disease.

In the second model, it is proposed that antigenic

fragments from foreign agents (or self peptides in the case
of autoimmune diseases) are selectively bound, with extreme
efficiency, into the antigen binding groove of a particular
MHC molecule.sa

Hence, only persons expressing that specific

MHC molecule would be able to mount an immune response to
that specific antigenic determinant of the disease-causing
agent.
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· In another · hypothesis it is postulated that MHCassociated diseases arise from molecular mimicry that exists
between the MHC molecule and the pathogenic agent.S9,60

In

this model it is suggested that antigenic similarities occur
or are shared between an etiological agent and the MHC
disease associated molecule .

.Such similarities could result

in an infection unchallenged because the host would lack
those clones specific for MHC self-peptides that were
eliminated during negative selection.

In other words, the

host would not have any T-cells able to recognize the
infectious · agent.

Alternatively, if MHC-derived peptides

were not utilized during negative selection, antigenic
similarities could provoke a strong immune response to self
tissues causing considerable tissue damage.

This model, in

which antigenic similarities between a pathogen and MHC
molecules are proposed, is also known as the shared epitope
hypothesis. 61,62

In several :studi-es -molecular mimicry in

disease states have been implicated.63
Finally, in a fourth hypothesis it is proposed that it
is the T-cell repertoire determined by the MHC profile of an
individual that is critical to the pathogenesis of a disease.
Certain TCR specificities may be necessary to induce
pathogenesis of a particular disease.

These required

specificities may only be present in an individual with a
specific HLA allotype.
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A number of research groups are studying the
hypervariable regions

(HVRs) of HLA molecules in an effort to

link specific sequences within these areas to disease states.
The MHC antigen subtypes DRB1*0401 and DRB1*0101 have been
associated with rheumatoid arthritis

(RA) . 64,65 For RA, it is

believed that the basis for such associations is the
existence of an amino acid sequence that is common between
the third HVR of the beta chain of the RA associated MHC
,"illeles and an epitope of an infectious agent.

62,66

For

example, one study of rheumatoid arthritis patients found
croHs-reactivity between the Escherichia coli heat shock
protein dnaJ and the DRB1*0401 molecule.59

The cross-

reactivity suggested an epitope shared by both proteins.
Another study, also including rheumatoid arthritis patients,
determined the existance of a highly homologous sequence
between a DR4 molecule and an Epstein-Barr virus
glycoprotein. 60

In both cases, the · sequence displaying

homogenecity was located in the · third ·hypervariable region of
the HLA molecule. Exactly how MHC molecules affect
susceptibility to RA is not known; however, the HVRs of the
MHC molecules may control the binding of a arthritogenic
peptide . 67, 68
Peptides from the third hypervariable region of MHC DR4
alleles generally elicit immune responses in patients with RA
and normal subjects as shown by Salvat et al.69

It may be
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evident that MHC-derived peptides are not functional in the
negative selection process in the thymus.

However, in the

same study the HLA DRB1*0401 allele was found to be tolerant
in the same group of subjects, thus displaying a uniqueness
of activity.

The HLA DRB1*0401 subtype is that allele found

in the extended haplotype B44-SC30-DR4.
The findings in this study, increased frequencies of the
extended haplotype B44-SC30-DR4 and the C4B null allele in
autistic subjects, are evidence for a possible association
-

between autism and the major histocompatibility complex.
Further studies may provide an actual relationship
responsible for this association.
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